Tuesday, 26 May 2015

Noteworthy ASCO findings

Let's collect anything interesting you picked up when going through the ASCO abstracts or online communication or publications or anything else related to ASCO 2015 under here- together we see more!


  1. Abstract of high interest although not a big surprise anymore: ipilimumab+ nivolumab almost doubled progression free survival in comparison with ipilimumab alone: 8,9 vs 4,7 months Overall response rate was 60% for combi vs 11% for IPI alone. No complet response was observed in the IPI arm. Also better responses rates on combi - for the patients with poor prognostic factors. http://abstracts.asco.org/156/AbstView_156_144615.html

  2. http://abstracts.asco.org/156/AbstView_156_148865.html Here, data from a very small cohort- encouraging use of pembrolizumab for patients with metastatic uveal melanoma. One patient had complete response, one - partial response and one-stable disease. PFS was 12.2 weeks and two patients are still receiving therapy.

  3. http://abstracts.asco.org/156/AbstView_156_152690.html - ...and here is a study (8 cases) on the etiology of uveal melanoma showing that distinctive agents might cause the disease.

  4. Dabrafenib +Trametinib vs Dabrafenib (CombiD) - data from live asco presentation today via Bettina -
    29% reduction in risk of death combo over monoteraphy
    25.1 vs 18.7 months PFS in favour of the combo
    2-year OS- > 50% on combination
    no data in the abstract http://abstracts.asco.org/156/AbstView_156_149861.html

  5. Clinical characteristics correlated with higher response to pembrolizumab
    -the data are from a phase I trial - 110 patients and ORR = 40%
    Higher ORR reported when:
    - LDH ≤ normal (ORR 52.2%),
    - no previous ipilimumab (ORR 48.3%),
    - presence of lung metastasis (ORR 52.8%).
    Patients with liver metastasis had worse response (ORR 18.4%), as did those with liver and lung metastases (ORR 31.3%)

  6. ASCO 2015: Complete Lymph Node Dissection Does Not Improve Survival in Patients With Melanoma and Micrometastases - the median follow-up of 35 months shows no significant differences in 3-year and 5-year recurrence-free survival and melanoma-specific survival. http://www.ascopost.com/ViewNews.aspx?nid=28616&utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=4210292

  7. This comment has been removed by the author.

  8. Linked to this article Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930354/, a presentation of Dummer ''he recommends cycling through targeted therapies: immunotherapies and then going back on targeted -a more holistic approach.

  9. Related to an ASCO presentation - Efficacy of MEK Inhibition in Uveal Melanoma http://jama.jamanetwork.com/article.aspx?articleid=1881312
    on the drug selumetinib vs chemotheraphy in uveal melanoma:
    - median survival 9.1 months on chemotherapy vs 11.8 months selumetinib
    - PFS - 7 weeks chemo vs 15.9 weeks selumetinib
    - OS - no improvement
    - selumetinib is giving fast responses, good PFS but not improvement in OS.
    ( it can be good as a ''bridge'')

  10. TAPUR- a Non Randomized Clinical Trial collecting real-world data in various cancers http://www.ascopost.com/ViewNews.aspx?nid=28617&utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=4210292

  11. This comment has been removed by the author.

  12. Neoadjuvant BRAF (dabrafenib) and MEK (trametinib)

  13. Adjuvant anti-PD-1 clinical trials- http://abstracts.asco.org/156/AbstView_156_151015.html
    Immune markers suporting the use of anti-PD1 as adjuvant theraphy

  14. Circulating melanoma cells (CMC) is linked with high risk recurrence in stage III melanoma patients - http://meetinglibrary.asco.org/content/152274-156

  15. BRAFi ENCO (LGX818) and MEKi BINI (MEK162) -- each shown promising single-agent activity in BRAFV600–mutant melanoma 78 and 72% respectively confirmed RR in phase Ib/II. - http://abstracts.asco.org/156/AbstView_156_146432.html
    Related -- a Ph III trial Columbus with these agents (US and Europe) https://clinicaltrials.gov/ct2/show/study/NCT01543698#contacts

  16. This comment has been removed by the author.

  17. IPILIMUMAB and T-VEC (oncolytic virus) http://abstracts.asco.org/156/AbstView_156_151884.html
    - Overall Response Rate -56%
    - Complete Responses -33%
    - Durable Response Rate -44%.
    - Median progression-free survival (PFS) -10.6 months
    - Median overall survival (OS) - not reached;
    - 12-month and 18-month survival- 72.2% and 67%.
    - 50% of uninjected lesions responded
    Phase 2 (ipi vs T-VEC+ipi) is ongoing